Oncternal Therapeutics, Inc.

NasdaqCM:ONCT Voorraadrapport

Marktkapitalisatie: US$4.4m

Oncternal Therapeutics Dividend

Dividend criteriumcontroles 0/6

Oncternal Therapeutics does not have a record of paying a dividend.

Belangrijke informatie

n/a

Dividendrendement

2.2%

Terugkoop Rendement

Totaal aandeelhoudersrendement2.2%
Toekomstig dividendrendementn/a
Dividendgroein/a
Volgende betaaldatum dividendn/a
Ex-dividenddatumn/a
Dividend per aandeeln/a
Uitbetalingsration/a

Recente dividendupdates

Geen updates

Recent updates

We Think Some Shareholders May Hesitate To Increase Oncternal Therapeutics, Inc.'s (NASDAQ:ONCT) CEO Compensation

Jun 14
We Think Some Shareholders May Hesitate To Increase Oncternal Therapeutics, Inc.'s (NASDAQ:ONCT) CEO Compensation

Can Oncternal Therapeutics (NASDAQ:ONCT) Afford To Invest In Growth?

Mar 03
Can Oncternal Therapeutics (NASDAQ:ONCT) Afford To Invest In Growth?

Here's Why We're A Bit Worried About Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation

Nov 06
Here's Why We're A Bit Worried About Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation

Oncternal Therapeutics (NASDAQ:ONCT) Will Have To Spend Its Cash Wisely

Jul 12
Oncternal Therapeutics (NASDAQ:ONCT) Will Have To Spend Its Cash Wisely

We're Keeping An Eye On Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate

Jan 12
We're Keeping An Eye On Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate

FDA clears Oncternal to proceed with dose escalation study for lymphoma car-T therapy

Oct 03

Oncternal Therapeutics begins phase 3 study of zilovertamab

Sep 27

Oncternal Therapeutics: Selling For Under Cash Value

Sep 02

Oncternal Therapeutics GAAP EPS of -$0.23 beats by $0.02, revenue of $0.2M misses by $0.26M

Aug 09

Here's Why We're Watching Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation

Aug 07
Here's Why We're Watching Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation

Oncternal to collaborate with an AbbVie company for its phase 3 lymphoma study

Jul 14

Oncternal Therapeutics: As Phase 2 Study Matures, Data Continues To Improve

Jun 07

We're Keeping An Eye On Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate

Apr 12
We're Keeping An Eye On Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate

Oncternal Therapeutics: Trading Near Cash With Impressive Results

Jan 04

Oncternal Therapeutics (NASDAQ:ONCT) Is In A Good Position To Deliver On Growth Plans

Nov 09
Oncternal Therapeutics (NASDAQ:ONCT) Is In A Good Position To Deliver On Growth Plans

Oncternal Therapeutics: Keep An Eye On This Biopharmaceutical Company

Oct 10

Oncternal: Solid Data In 2 Cancers With High Unmet Need

Jun 17

We Think Oncternal Therapeutics (NASDAQ:ONCT) Can Afford To Drive Business Growth

May 05
We Think Oncternal Therapeutics (NASDAQ:ONCT) Can Afford To Drive Business Growth

Should Oncternal Therapeutics (NASDAQ:ONCT) Be Disappointed With Their 81% Profit?

Mar 01
Should Oncternal Therapeutics (NASDAQ:ONCT) Be Disappointed With Their 81% Profit?

Stabiliteit en groei van betalingen

Dividenden ophalen

Stabiel dividend: Insufficient data to determine if ONCT's dividends per share have been stable in the past.

Groeiend dividend: Insufficient data to determine if ONCT's dividend payments have been increasing.


Dividendrendement versus markt

Oncternal Therapeutics Dividendrendement versus markt
Hoe verhoudt ONCT dividendrendement zich tot de markt?
SegmentDividendrendement
Bedrijf (ONCT)n/a
Markt onderkant 25% (US)1.5%
Markt Top 25% (US)4.5%
Gemiddelde industrie (Biotechs)2.2%
Analist prognose (ONCT) (tot 3 jaar)n/a

Opmerkelijk dividend: Unable to evaluate ONCT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Hoog dividend: Unable to evaluate ONCT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Winstuitkering aan aandeelhouders

Verdiendekking: Insufficient data to calculate ONCT's payout ratio to determine if its dividend payments are covered by earnings.


Contante uitbetaling aan aandeelhouders

Kasstroomdekking: Unable to calculate sustainability of dividends as ONCT has not reported any payouts.


Ontdek bedrijven met een sterk dividend